Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07572383 · ClinicalTrials.gov registry record · Phase 2
Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis
A Phase 2 study, sponsored by Peter Caravan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07572383: Recruiting Phase 2 study, sponsored by Peter Caravan.
NCT07572383 is a Phase 2 study that is actively recruiting participants, run by Peter Caravan. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07572383, a Phase 2 study, is actively recruiting participants, sponsored by Peter Caravan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).
Primary Outcome
Changes in lung collagen uptake will be measured using the PET probe \[68\]Ga-CBP8. Measurements will be made using the mean of the upper quartile of standardized uptake values (SUVmax25). Primary \[68Ga\]CBP8-PET outcome.
Interventions
- DRUG [68Ga]CBP8
- DRUG Gadoterate Meglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT07572383 shows while recruiting
NCT07572383 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which [68Ga]CBP8 is the first listed.
NCT07572383 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07572383 about?
NCT07572383 is a clinical study titled "Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis". The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopath...
What is the current status of trial NCT07572383?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-04. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07572383?
The interventions under investigation include: [68Ga]CBP8 (DRUG), Gadoterate Meglumine (DRUG).
Who is sponsoring clinical trial NCT07572383?
This trial is sponsored by Peter Caravan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07572383's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia